Cytovation melanoma study under way
Source: LABIOTECH.eu, February 2023
Cytovation ASA, a Norwegian clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class targeted tumor membrane immunotherapy, announces that the first patient has been dosed in its phase 2a study.
The trial is investigating CyPep-1 monotherapy in patients with advanced melanoma refractory to checkpoint inhibitors (CPIs).
The study is an expansion arm of its ongoing phase 1/2 CICILIA trial in solid tumors, which is being conducted in The Netherlands, France, and Spain. The phase 2a study builds on encouraging data from the first phase of the trial, which has demonstrated a favorable safety profile for CyPep-1 monotherapy along with strong early signals of efficacy in several tumor types.